NeuroLaunch, the first major worldwide program for neuroscience technology businesses, is taking Atlanta by storm in a rolling 90-day program aimed to give participants and their companies the tools needed to succeed, including seed funding, mentorship, and other resources, such as access to top research centers.

A $4 million boon is going to Waltham, Mass.-based biomedical company XTuit Pharmaceuticals. The cancer therapy researchers behind XTuit plan to raise an additional $6 million in investments, according to a recent filing with the U.S. Securities and Exchange Commission.

A novel PET technique combining a diagnostic radionuclide with a therapeutic agent can now map the potential results of therapy for advanced renal cell carcinoma, according to a study published Dec. 4 in the Journal of Nuclear Medicine. 

The genomics market is expected to grow at an annual compound growth rate of 7.28 percent from 2013 to 2018, according to a recent market report from market research firms Infiniti Research Limited and TechNavio. 

The diagnostic imaging markets in Brazil, Russia, India and China—known as the BRIC markets, are expected to grow at a compound annual growth rate of 10.5 percent, reaching $7.6 billion within the next four years.

PET has dominated the amyloid imaging ring for several years now, but a preclinical study is showing some signs that SPECT could give PET a run for its money eventually, especially in translational research, according to a study published Dec. 4 in the Journal of Nuclear Medicine.

A protein that suppresses immune response could tell researchers how patients taking a novel cancer immunotherapy will fare, Yale officials announced Nov. 26. The discovery could predict immune response in the treatment of a wide variety of cancers.

Cambridge, Mass., based biomedical company Biogen Idec announced encouraging results of a phase II drug targeting amyloid in Alzheimer’s patients at a Deutsche Bank conference in Boston today.